Award
NIH Reporter #1F31CA306268-01A1
Targeting ALC1 ATPase Activity as a New Synthetic Lethal Strategy for BRCA-Mutant Cancers
Recipient
Washington University
Award Amount
$50,114.00
Ceiling
$50,114.00
Awarded
August 20, 2026
Identifier
1F31CA306268-01A1
A National Cancer Institute-funded research fellowship project studying ALC1 ATPase as a potential synthetic-lethal therapeutic target for BRCA-mutant cancers.
Description
NIH research training project investigating the basis of synthetic lethality between ALC1 ATPase activity and BRCA deficiency, and identifying ALC1 ATPase regions relevant to potential inhibitor development for BRCA-mutant cancers. The project period is August 20, 2026–August 19, 2028.